First Opinion Adewole Adamson, Vishal Patel, and H. Gilbert Welch Doing more cancer screening won’t reduce Black-white health disparities
Biotech Jonathan Wosen STAT Plus: Grail announces layoffs as it looks to push forward blood-based cancer detection test
Health Elizabeth Cooney As Covid deaths drop, heart disease and cancer remain leading causes of death
Health Angus Chen Scientists are starting to uncover how neighborhood can affect the biology of cancer
First Opinion Gebra Cuyun Carter and Caitlin Kubler Address liquid biopsy disparities today to ensure equity in outcomes tomorrow
Biotech Andrew Joseph STAT Plus: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer
First Opinion Darrell Rigel Rising rates of skin cancer: The cost of FDA’s inaction on novel sunscreen products
In the Lab Angus Chen STAT Plus: With Biden’s departure in sight, advocates seek to preserve gains of Cancer Moonshot
In the Lab Alia Sajani STAT Plus: Parasite engineered to treat brain development disorder in mice shows potential in study
Biotech Matthew Herper STAT Plus: In a big step for liquid biopsy, FDA approves a blood screening test for colorectal cancer
Morning Rounds Brittany Trang Morning Rounds: Three new bird flu cases in humans brings total to 13 in U.S.
Politics Rohan Rajeev STAT Plus: Kamala Harris’ views on health care were shaped by her mother, cancer researcher Shyamala Gopalan
Biotech Allison DeAngelis STAT Plus: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies
Pharma Andrew Joseph STAT Plus: Novartis hedges on when it might submit myelofibrosis drug for approval
In the Lab Angus Chen Bone marrow donors needn’t be perfect match, study says, paving way for more equitable access
Exclusive Mohana Ravindranath STAT Plus: A cancer care startup is making a new bet with payers and providers: only pay if it works
In the Lab Alia Sajani and Angus Chen CAR-T cell therapy’s complications, as well as its benefits, become clearer in ‘flurry’ of cancer studies
Adam's Take Adam Feuerstein STAT Plus: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet?
Health Nicholas Florko Medicaid is paying millions for salty, fat-laden ‘medically tailored’ cheeseburgers and sandwiches